Rajini Reddy

Director of Business Development at Mitotherapeutix. Dr. Reddy is a scientist with both academic and industry familiarity, have considerable experience in laboratory research and expert at managing a laboratory research team. She is schooled about Entrepreneurship and attended multiple workshops to imbibe on the different aspects of business and technology commercialization and also trained to write grants by NIH and SBIR/STTR. Dr. Reddy is working on the scientific aspects of Mitotherapeutix along with business development. She has been a part of the R & D team of the start-up company LambdaVision to develop bacteriorhodopsin based retinal prosthetic for treating retinal degenerating diseases and established the cytotoxic study of bacteriorhodopsin in cultured retinal pigmented epithelium cells. Dr. Reddy did her postdoctoral research at the Department of Ophthalmology, Yale University where she Investigated the role of mitochondrial Uncoupling Protein UCP2 and its functional relevance with regard to physiological and pathological death of the retinal ganglion cells and established that UCP2 transgenic mice exhibited significantly less cell death when exposed to few excitotoxins. She received her Masters in Science in Physiology from Bangalore University and her Ph.D in Neuroscience from National Institute of Mental Health & Neurosciences.